Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Preclinical evaluation of gastrin derivatives labelled with 111In: radiolabelling, affinity profile and pharmacokinetics in rats

L. Melicharova, A. Laznickova, M. Laznicek

. 2014 ; 158 (4) : 544-551. [pub] 20130927

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17006106

BACKGROUND: Cholecystokinin receptor subtype 2 (CCK-2) is overexpressed in various tumours like medullary thyroid carcinomas and small cell lung cancer. Radiolabelled peptides that bind with high affinity and specificity to CCK-2 receptors, thus hold great potential for visualizing such tumours. METHODS: We compared four 111In labelled gastrin analogues, called minigastrins (MG), namely MG11, MG45, MG47 and MG48 linked to metal chelating DOTA in preclinical experiments. The radiolabelled peptides were tested for peptide binding in CCK-2 receptor-bearing cell line AR42J and for their pharmacokinetics in normal rats. RESULTS: The experiments suggest that all gastrin analogues had similar and relatively rapid internalization into AR42J cells. Binding to CCK-2 receptors in AR42J cells was saturable for all agents but there were some differences in receptor affinity. This biodistribution study in rats showed a rapid decrease in blood radioactivity, predominantly renal clearance and saturable uptake of the radiopharmaceutical and/or its metabolites in the CCK-2 receptor-positive stomach. Higher kidney accumulation of radioactivity was only found for 111In-DOTA-minigastrin 48. CONCLUSIONS: The data suggest that the 111In-DOTA-minigastrin analogues studied are promising candidates for the scintigraphy of CCK-2 receptor-expressing tumours; 111In-DOTA-MG47 and 111In-DOTA-MG11 are the most promising.

000      
00000naa a2200000 a 4500
001      
bmc17006106
003      
CZ-PrNML
005      
20170307121820.0
007      
ta
008      
170210s2014 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2013.064 $2 doi
035    __
$a (PubMed)24108197
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Melicharová, Ludmila, $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic $d 1962- $7 xx0105436
245    10
$a Preclinical evaluation of gastrin derivatives labelled with 111In: radiolabelling, affinity profile and pharmacokinetics in rats / $c L. Melicharova, A. Laznickova, M. Laznicek
520    9_
$a BACKGROUND: Cholecystokinin receptor subtype 2 (CCK-2) is overexpressed in various tumours like medullary thyroid carcinomas and small cell lung cancer. Radiolabelled peptides that bind with high affinity and specificity to CCK-2 receptors, thus hold great potential for visualizing such tumours. METHODS: We compared four 111In labelled gastrin analogues, called minigastrins (MG), namely MG11, MG45, MG47 and MG48 linked to metal chelating DOTA in preclinical experiments. The radiolabelled peptides were tested for peptide binding in CCK-2 receptor-bearing cell line AR42J and for their pharmacokinetics in normal rats. RESULTS: The experiments suggest that all gastrin analogues had similar and relatively rapid internalization into AR42J cells. Binding to CCK-2 receptors in AR42J cells was saturable for all agents but there were some differences in receptor affinity. This biodistribution study in rats showed a rapid decrease in blood radioactivity, predominantly renal clearance and saturable uptake of the radiopharmaceutical and/or its metabolites in the CCK-2 receptor-positive stomach. Higher kidney accumulation of radioactivity was only found for 111In-DOTA-minigastrin 48. CONCLUSIONS: The data suggest that the 111In-DOTA-minigastrin analogues studied are promising candidates for the scintigraphy of CCK-2 receptor-expressing tumours; 111In-DOTA-MG47 and 111In-DOTA-MG11 are the most promising.
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a komplexní sloučeniny $7 D056831
650    _2
$a gastriny $x farmakokinetika $x farmakologie $7 D005755
650    _2
$a heterocyklické sloučeniny monocyklické $7 D006573
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a peptidy $7 D010455
650    _2
$a radiofarmaka $7 D019275
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a receptor cholecystokininu B $x metabolismus $7 D043887
650    _2
$a tkáňová distribuce $7 D014018
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lázníčková, Alice, $d 1948- $7 nlk19990073515 $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove
700    1_
$a Lázníček, Milan, $d 1947- $7 nlk19990073514 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 4 (2014), s. 544-551
856    41
$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170210 $b ABA008
991    __
$a 20170223085944 $b ABA008
999    __
$a ok $b bmc $g 1192293 $s 966753
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 158 $c 4 $d 544-551 $e 20130927 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20170210

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...